What Instanyl Treats: Main Uses and Benefits

This medication is used for managing distressing symptoms within established pain management regimens, focusing on sudden and severe symptom escalation.

---

Management of Severe, Unpredictable Breakthrough Pain

This therapeutic domain is applied in addressing the short, intense pain flares that unexpectedly pierce through the pain control provided by a patient's regular, long-acting opioid medication. It is relevant for managing high-intensity episodes of pain, typically associated with cancer, providing supportive symptomatic assistance when conventional around-the-clock analgesia is overwhelmed. The medication is commonly used for managing breakthrough pain in adult patients who are opioid-tolerant.

“Used in scenarios requiring short-term symptomatic support, this medication may assist with easing the symptom load.”

---

Symptom Support for Opioid-Tolerant Adults

The medication is commonly used for managing conditions in adult patients who are already tolerant to, and receiving, continuous opioid therapy for persistent chronic pain. This patient criterion supports its use in situations requiring short-term symptomatic support, providing support that contributes to improved comfort, helping the patient cope more steadily with acute distress. It is commonly used when symptoms become temporarily overwhelming and supportive relief is needed.

Quick Fact: Relevant in conditions characterized by Severe, Episodic Pain Flares

Instanyl (fentanyl nasal spray) is a prescription medicine with strict eligibility criteria due to the risk of life-threatening respiratory depression. It is intended only for the management of breakthrough cancer pain in adults (18 years and older).

Instanyl is strictly limited to patients who are opioid-tolerant. This means they must already be receiving and tolerant to continuous, around-the-clock opioid therapy for their underlying persistent cancer pain. Opioid tolerance is generally defined as taking a minimum daily equivalent of 60 mg of oral morphine for a week or longer.

Populations Contraindicated (Must Not Use)	Populations for Special Consideration
Opioid non-tolerant patients	Elderly or cachectic (debilitated) patients
Severe respiratory depression or severe obstructive lung conditions	Patients with moderate to severe hepatic or renal impairment
Known hypersensitivity to fentanyl	Patients with chronic pulmonary diseases, increased intracranial pressure, or head injury
Treatment for acute or postoperative pain	Pregnant or breastfeeding patients (use generally not recommended)
Patients being treated with sodium oxybate	The safety and efficacy in the pediatric population have not been established and use is not indicated. Patients with previous facial radiotherapy or recurrent nosebleeds (epistaxis) must not use this medicine.

Interactions with Other Medicines and Products

The interaction profile of Instanyl (fentanyl nasal spray) is primarily defined by its clearance pathway and potential for additive central nervous system effects, as documented in regulatory information.

Documented Interaction Categories

Category	Practical Regulatory Constraint
CYP3A4 Enzyme Modifiers	Strong inhibitors (e.g., ritonavir, ketoconazole) significantly increase fentanyl exposure ( AUC, C max), requiring careful monitoring for extended periods. Inducers (e.g., rifampin) may decrease efficacy.
CNS Depressants	Coadministration with substances like alcohol, benzodiazepines, or other opioids increases the risk of profound sedation, respiratory depression, coma, and death due to additive effects.
Serotonergic Agents	Use with medicines affecting the serotonin system (e.g., SSRIs, MAO Inhibitors) carries the risk of Serotonin Syndrome. MAO Inhibitors must not have been taken within 14 days of Instanyl.

Other Constraints and Notes

Concomitant use with mixed agonist/antagonist opioids (e.g., nalbuphine, buprenorphine) is generally not recommended as they may reduce the pain-relieving effect. Nasal decongestants should be avoided due to the potential for reduced absorption. In patients who are elderly, frail, or have significant hepatic or renal impairment, caution is necessary, as reduced clearance may heighten the risk of adverse effects from any documented interaction.

Instanyl is a formulation of fentanyl, which functions as a mu-opioid receptor (mu-OR) pure agonist with lower affinity for delta- and kappa-opioid receptors. These mu-ORs are class A G protein-coupled receptors (GPCRs), highly concentrated on neuronal membranes throughout the central nervous system, including the dorsal horn of the spinal cord and periaqueductal gray matter.

Binding of fentanyl to the mu-OR induces a conformational change that activates an intracellular inhibitory heterotrimeric G( i/o)-protein. The activated G( i/o)-protein's alpha-subunit inhibits the membrane-bound enzyme adenylyl cyclase (AC), reducing the conversion of ATP to the second messenger cyclic adenosine monophosphate (cAMP). Simultaneously, the betagamma-subunit complex of the G( i/o)-protein modulates ion channel function by promoting the opening of G protein-coupled inwardly rectifying potassium channels (GIRK) and inhibiting N-type voltage-gated calcium channels.

These intracellular actions result in a downstream cascade: the increased potassium efflux and decreased calcium influx lead to neuronal hyperpolarization and a reduction in neuronal excitability. The primary systemic physiological consequence of this modulation is the inhibition of presynaptic release of nociceptive neurotransmitters, thereby modifying signal transmission in the pathways associated with somatosensation and descending inhibitory control.

Instanyl is administered via the Intranasal route as a solution spray, exclusively for use in opioid-tolerant adults. Administration involves the patient being in an upright position (sitting or standing) during delivery.

The core principle of use is individual dose titration. All patients must initiate treatment with one dose of 50 mug administered into a single nostril. The dose is adjusted upwards in increments by a healthcare professional until the effective strength is identified, which is then used for maintenance. If pain is not adequately relieved by the first dose, a second dose of the same strength may be administered at the earliest after 10 minutes to treat the same pain episode.

The frequency of administration is strictly controlled. The medication is intended for as-needed (PRN) use, with a restriction of treating no more than four breakthrough pain episodes per day. A minimum interval of 4 hours must separate the treatment of two different breakthrough pain episodes.

Before initial use, or if the device has not been used for more than seven days, the nasal spray must be primed by actuating it until a fine mist appears, ensuring the device is ready to deliver the correct dose. Dose titration requires caution in older adults and patients with hepatic or renal impairment due to potential physiological changes. The safety and efficacy of this medicine are not established for pediatric patients below 18 years of age.

Research Evidence / Overview of Studies for Instanyl

Evidence for use in Breakthrough Cancer Pain

Research has primarily focused on the use of this product in adults with cancer experiencing breakthrough pain (BTP) who are already receiving stable, ongoing opioid therapy. Studies conducted included randomized, double-blind, placebo-controlled trials. These trials were designed to explore how this product affects short-term changes in pain intensity, specifically measuring differences on patient-reported scales at defined time points, such as 10 minutes following administration. Findings from these controlled studies reported measured changes in pain intensity that were observed at the 10-minute mark when compared to placebo. This evidence contributes to understanding symptom patterns in the study populations.

Long-term studies and follow-up

Research has also included prospective observational studies over defined, shorter durations, typically up to three months. These observational studies monitored the product’s use in real-life settings, examining outcomes such as the achievement of a maintenance dose and patient-reported measures of treatment satisfaction and the impact of pain on daily life. Evidence highlights patterns observed during this three-month period, but long-term outcomes extending beyond this timeframe are not fully established, and follow-up durations were limited.

Evidence in special populations

Existing research provides limited information for certain specific populations. Studies have monitored older adult patients (those over 65 years of age), and evidence suggests this group may exhibit higher sensitivity to the product's effects. Furthermore, data remains limited for patients with debilitating conditions, such as cachexia, as well as those receiving particularly high daily doses of background opioid medication. This product was not evaluated for use in children under 18 years of age, and data for this group are currently not available.

What is still uncertain about Instanyl

The body of evidence, while providing insight into short-term changes in pain intensity, is subject to limitations. Long-term outcomes are not fully established. Comparative evidence against all other forms of rapidly-acting opioids is lacking, and data for older and severely debilitated patient groups remain insufficient for broad conclusions. Results apply only to the populations studied under the specific conditions of the research.

Key Studies & References Study Details | NCT01045603 | Instanyl® Non-Interventional Study | ClinicalTrials.gov

Common questions about Instanyl (FAQ)

Q: What is Instanyl?

A: Instanyl is a medication that contains the active ingredient fentanyl. It belongs to a class of medicines called opioid analgesics, which are used to treat pain. Specifically, Instanyl is used for the treatment of breakthrough pain in adults with cancer who are already receiving and are tolerant to ongoing opioid therapy for their persistent cancer pain. Breakthrough pain is a temporary flare-up of pain that occurs even when a patient is taking their regular pain medication.

Q: How should I take Instanyl?

A: Instanyl is a nasal spray that is administered into one nostril. The dose is usually determined by your doctor and is based on your individual pain relief needs. You should not spray Instanyl into both nostrils at the same time. Instanyl is typically taken at the onset of a breakthrough pain episode, and you must wait a minimum of 10 minutes before taking a second dose for the same episode of pain if needed. You should never take more than four doses in a single hour.

Q: What should I do if I miss a dose of Instanyl?

A: Instanyl is used only when needed for episodes of breakthrough pain. Since it is not a regularly scheduled medication, there is no risk of missing a dose in the traditional sense. You should only use it as directed by your healthcare provider when a breakthrough pain episode occurs.

Q: What are the common side effects of Instanyl?

A: As with all medications, Instanyl can cause side effects. Common side effects (which may affect up to 1 in 10 people) include:

• Dizziness, drowsiness, or sedation
• Headache
• Nausea and vomiting
• Constipation
• Dry mouth
• Nasal discomfort, such as irritation or nosebleeds

Less common but serious side effects include severe sleepiness, slow or shallow breathing, and signs of an allergic reaction. If you experience serious side effects, seek medical attention immediately.

Q: Can I take Instanyl with other medications?

A: Taking Instanyl with certain other medications can be dangerous. It is critical to inform your doctor or pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. Medications that affect the central nervous system (like other opioids, sedatives, or sleeping pills) or those that affect the metabolism of Instanyl (certain CYP3A4 inhibitors) can increase the risk of serious side effects, including severe respiratory depression (slowed breathing) or coma. Alcohol must be avoided while taking Instanyl as it can dangerously increase the sedative effects.

Official Storage Requirements

Instanyl (fentanyl nasal spray) must be stored at a temperature below 30 C and must not be frozen. To ensure child safety, the medication must always be kept in its original child-resistant outer box and stored upright. Due to its high potency as an opioid, the product must be kept out of the sight and reach of children at all times.

Handling and Disposal

Proper disposal is mandatory for both used and any unused Instanyl solution. The medicine must be returned systematically to the pharmacy or physician for appropriate pharmaceutical waste handling, in accordance with local regulatory requirements. If a take-back program is unavailable, some regulations allow the medication to be disposed of by flushing down the toilet to prevent accidental exposure, as fentanyl is a high-risk substance.